99 results
Page 3 of 5
8-K
EX-99.1
76pad7
6 May 21
Gossamer Bio Announces First Quarter 2021 Financial Results and Provides Corporate Update
8:06am
8-K
EX-99.1
rcqnph
20 Apr 21
Gossamer Bio Announces Executive Management Transition and Promotion of Laura Carter, Ph.D., to Chief Scientific Officer
4:44pm
8-K
EX-99.1
s5j gniwy
25 Feb 21
Gossamer Bio Announces Fourth Quarter and Full-Year 2020 Financial Results and Provides Business Update
8:00am
8-K
EX-99.1
2srw032v
10 Nov 20
Gossamer Bio Announces Third Quarter 2020 Financial Results and Provides Corporate Update
4:14pm
8-K
EX-99.2
tkj 3vmwztiv89e3
13 Oct 20
Gossamer Bio Announces Topline Results for Phase 2 Trials of Oral GB001 in Asthma and Chronic Rhinosinusitis
7:40am
8-K
EX-99.1
q27sxn4e c3
11 Aug 20
Gossamer Bio Announces Second Quarter 2020 Financial Results and Provides Corporate Update
4:30pm
8-K
EX-1.2
pjtk8mzphvyg
21 May 20
Gossamer Bio Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Senior Notes due 2027
4:06pm
8-K
EX-1.1
3ua3jkxx
21 May 20
Gossamer Bio Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Senior Notes due 2027
4:06pm
8-K
7w72c onfo8
21 May 20
Gossamer Bio Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Senior Notes due 2027
4:06pm
8-K
EX-99.1
jeeqrc7npv2j
21 May 20
Gossamer Bio Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Senior Notes due 2027
4:06pm
8-K
EX-99.2
6dpc52t 6y5i4m
21 May 20
Gossamer Bio Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Senior Notes due 2027
4:06pm
424B5
pj9zt
19 May 20
Prospectus supplement for primary offering
5:11pm
424B5
0fk7em rl9zh8zt2
19 May 20
Prospectus supplement for primary offering
5:08pm
FWP
0kr8p
19 May 20
Free writing prospectus
6:06am
FWP
515p4rgcuw0jysevlbz
18 May 20
Free writing prospectus
5:02pm